Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 12/20 | 0.70 |
| ▸ | CTSL | P07711 | 5/20 | 0.66 |
| ▸ | CTSS | P25774 | 3/20 | 0.66 |
| ▸ | CTSB | P07858 | 3/20 | 0.66 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7285570 | 0.94 | CAPN1 (0.66) | CTSKCTSLCTSSCTSBCAPN1 | |
| SCHEMBL7285558 | 0.94 | CAPN1 (0.66) | CTSKCTSLCTSSCTSBCAPN1 | |
| SCHEMBL9600765 | 0.90 | CTSK (0.63) | CTSKCTSLCTSSCTSBCAPN1 | |
| SCHEMBL29577004 | 0.90 | CAPN1 (0.64) | CTSKCTSLCTSSCTSBCAPN1 | |
| SCHEMBL29678442 | 0.90 | CAPN1 (0.64) | CTSKCTSLCTSSCTSBCAPN1 | |
| SCHEMBL8823928 | 0.90 | CTSK (0.73) | CTSKCTSLCTSSCTSBCAPN1 | |
| SCHEMBL8823980 | 0.90 | CTSK (0.73) | CTSKCTSLCTSSCTSBCAPN1 | |
| SCHEMBL13914028 | 0.90 | CTSK (0.63) | CTSKCTSLCTSSCTSBCAPN1 | |
| SCHEMBL13925094 | 0.90 | CTSK (0.60) | CTSKCTSLCTSSCTSBCAPN1 | |
| SCHEMBL4485017 | 0.89 | CTSK (0.59) | CTSKCTSLCTSSCTSBCAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4149552-A1 | COMPOSITIONS AND METHODS FOR INCREASING EFFICACY OF A DRUG | Healion Bio, Inc. (US) | 2023-03-22 | — | — | EP | disclosed |
| EP-4051109-A1 | METHODS FOR THE CHARACTERIZATION OF FLUID | NextGen Jane, Inc. (US) | 2022-09-07 | — | — | EP | disclosed |
| WO-2022072504-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASES | HEALION BIO, INC. (US) | 2022-04-07 | — | — | WO | disclosed |
| US-11007269-B2 | P53 degradation inducing molecule and pharmaceutical composition | TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) | 2021-05-18 | — | — | US | disclosed |
| US-20190314508-A1 | P53 DEGRADATION INDUCING MOLECULE AND PHARMACEUTICAL COMPOSITION | TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190314508-A1 | P53 DEGRADATION INDUCING MOLECULE AND PHARMACEUTICAL COMPOSITION | TP53, TP53BP1, MDM2 | CTSK 399/4885CTSL 669/4885CTSS 736/4885 |
| US-11007269-B2 | P53 degradation inducing molecule and pharmaceutical composition | TP53, TP53BP1, MDM2 | CTSK 399/4885CTSL 669/4885CTSS 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.